InsiderTrades

Form 4 for AVTX Avalo Therapeutics, Inc.

Accepted 2023-05-16 00:00:00 ET · period of report 2023-05-12 · accession 0001929354-23-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
MI 2023-05-16 2023-05-12+ AVTX Caissa Capital Management ltd. 10% P - Purchase $2.52 +4,379 1.35M +0.3% +$11.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2023-05-12 P A 2,285 $2.45 1,344,985 I See Footnote (1) — — (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
2 Common Common stock 2023-05-16 P A 379 $2.75 1,347,079 I See Footnote (1) — — (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
3 Common Common stock 2023-05-15 P A 1,715 $2.55 1,346,700 I See Footnote (1) — — (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive. (F1) Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.